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Next generation sequencing has provided information on actionable targets and 
biomarkers of response in oncology. In HCC, Wnt/CTNNB1 mutations characterize 
the immune excluded class (cold tumors) and might represent the biomarkers 
predicting resistance to immune checkpoint inhibitors. Large-scale validation of this 




MAIN TEXT:   
In this issue of Clinical Cancer Research, Harding et al provide the first report of 
prospective genotyping of advanced HCC and the potential implications for clinical 
decision-making [1]. Tumor profiling using the MSK-IMPACT custom panel for 
targeted exome sequencing (468 genes) was used to inform the treating physician 
about the actionable genomic alterations harbored by each tumor in 127 patients with 
advanced HCC [1]. This first-in-class study provides three main results that warrant 
attention: a) Around 25% of advanced tumors harbored actionable mutations, 
although overall only 6% of patients received matched therapeutic interventions; b) 
Oncogenic PI3K-MTOR alterations might predict sorafenib resistance, as described 
in 81 HCC treated patients, and c) Previously reported immune exclusion HCC class, 
characterized by Wnt/CTNNB1 mutations [2,3], might predict innate primary 
resistance to immune checkpoint inhibitors, as explored in 31 patients receiving these 
therapies. Despite some limitations pointed out by the authors related to the small 
sample size and lack of analysis of confounding factors predicting response, the 
current data provides novel insights in defining biomarker-driven responses in 
advanced HCC that deserve confirmation in prospective large-scale clinical 
investigations.  
In HCC, around 40% of patients are diagnosed at advanced stage when systemic 
therapies are indicated [2]. The multi-tyrosine kinase inhibitor (TKI) sorafenib was the 
first molecular targeted therapy that demonstrated survival benefit in advanced HCC 
cases [4]. More recently, additional TKIs (lenvatinib in first-line, and regorafenib, 
cabozantinib and ramucirumab in second-line) have demonstrated survival benefits in 
the setting of phase III trials. In addition, immune checkpoint inhibitors (nivolumab 
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and pembrolizumab, both in second-line) obtained accelerated FDA approval based 
upon phase II positive clinical signals [2]. In spite of such advancements, median 
survival of these patients is still limited to 12-13 months in front-line and 9-11 
months in second-line. No biomarkers are available for tailored treatments, except for 
AFP > 400 ng/mL in patients responding to ramucirumab. In this scenario, a deeper 
understanding of actionable targets in the clinical practice, mechanisms of 
response/resistance to identify biomarkers of response and synergies among 
treatments (immunotherapies (IOs) and TKIs/monoclonal antibodies (MAb)) are 
required to ultimately improve patients‟ survival.  
Deep-exome sequencing of HCC tumors has been reported in 1,200 cases [2,5]. 
These studies, mostly conducted in resected tumors, have delineated that the most 
prevalent oncogenic drivers in HCC (TERT, TP53, CTNNB1, AXIN1, ARID1A and 
ARID2) are currently not actionable. As described for other solid tumor malignancies, 
in HCC there is also a “long tail” of mutations, amplifications or deletions at a 
prevalence of <10%, among which some are amenable for targeted therapies. In this 
sense, 25% of such alterations have been defined as potentially targetable with the 
current drug armamentarium [5]. These include FGF19 and VEGFA amplifications, 
MET amplifications or mutations, mutations in PI3K-MTOR signaling (PI3KCA, PTEN, 
TSC1/2), among others. None of these potential biomarkers have reached a stage in 
clinical investigation to demonstrate survival benefits, although data with FGFR4 
inhibitors in tumors overexpressing FGF19 is promising.  
The current study demonstrates that a prospective genotyping approach in patients 
with advanced HCC is able to identify tumors (24%) with potentially actionable 
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alterations. None of them could receive biomarker-based approved drugs for this 
indication (level of evidence 1-2A) and only 6% of patients received either drugs 
approved for another indication (level 2B) or agents in active clinical developments 
with appealing biomarkers predicting responses (level of evidence 3A and B). 
Specifically, 5 patients were treated in second-line with either everolimus (based upon 
TSC1/2 alterations) or monoclonal antibodies against VEGFR2 and MET (due to 
VEGFR and MET amplifications). Thus, this study, which is the first to report a 
prospective genotyping of HCC patients aimed to inform decision-making, describes 
24% actionable mutations in advanced tumors, but ultimately only 6% of patients 
received matched therapeutics. Further approaches including large cohorts of 
patients are required to demonstrate the cost-effectiveness of this strategy. 
Biomarkers predicting response to sorafenib are lacking in advanced HCC [2]. 
Companion studies of the SHARP trial using blood-based biomarkers showed a non-
significant trend for sorafenib benefit in patients with high levels of c-Kit and low levels 
of HGF. Similarly, a recent study identified a gene signature able to predict sorafenib 
recurrence-free responders in the adjuvant setting after resection/local ablation, a 
result that warrants further validation [6]. Thus, after more than 10 years of research 
we lack biomarker guidance to identify sorafenib responders. Only clinical predictors 
of response, such as HCV-infected HCC and those with liver-only disease, have 
been associated with a greater benefit with this TKI. In this current study, Harding and 
colleagues report retrospectively that tumors harboring PI3K/MTOR mutations 
(PI3KCA, PTEN, TSC1/2) are more likely to be primary resistant to sorafenib (survival 
of 10.4mo vs 17.9mo in those without mutations). These mutational alterations 
accounted for 15% of the tested patients, a figure above the 5-10% published by 
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TCGA series or in a large meta-analysis [2]. Nonetheless, these results represent a 
positive signal that deserves further investigations. 
The most appealing data reported by Harding and colleagues refers to the first 
confirmation of the hypothesis that HCC ‘cold’ tumors -defined by Wnt/CTNNB1 
mutations [3]- are those refractory to immune checkpoint inhibitors [2,3] (Figure 1). In 
order to identify biomarkers of response to IOs, the authors correlated outcome with 
the mutational profile of 27 patients receiving monoclonal antibodies anti-PD-1/PD-L1 
(81%), or anti-CTLA-4, and combinations of anti-PD-1/PD-L1 with anti-CTLA-4, anti-
KIR or anti-LAG3 (19%) [1]. Immunotherapies are more likely to be efficacious in ‘hot’ 
tumors, as defined by the presence of tumor-infiltrated lymphocytes (TILs). In parallel, 
tumors displaying immune exclusion, the so-called „cold‟ tumors, are resistant to 
immunotherapies. In 2017 our group described a new molecular HCC classification 
based upon immune traits [2,5]. In brief, 30% of HCCs were enriched by TILs and 
with molecular features resembling melanomas responsive to immunotherapies, and 
were defined as HCC Immune class (Figure 1) [2,5]. Conversely, we observed that 
~30% of patients showed exclusion of TILs, enrichment in CTNNB1 mutations and 
known molecular fingerprints of primary resistance (HCC Exclusion class, Figure 1) 
[2,3]. Therefore, while tumors within the HCC Immune subtype may represent 
patients most likely to respond to immune checkpoint inhibitors, those within the HCC 
Exclusion class might represent those with innate resistance to anti-PD1/PD-L1 or 
similar therapies [2]. In their manuscript, Hardling et al. observed that 10 out of 27 
patients (37%) treated with IOs exhibited Wnt/CTNNB1 mutations (7 CTNNB1, 3 
AXIN1). Those 10 patients displaying an altered Wnt-β-catenin pathway were 
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refractory to immune checkpoint blockers (all had progressive disease as best 
response), with a trend to poorer median survival [9.1mo vs 15.2 mo in those without 
mutations). These results are in line with the seminal study in melanoma 
demonstrating that non-T-cell-inflamed phenotype displayed altered b-catenin 
signaling [7]. This data is the first clinical signal, to our knowledge, to provide a 
potential biomarker defining primary resistance to checkpoint inhibitors in HCC. 
Certainly, whether mutations in CTNNB1 and AXIN1 are true biomarkers of innate 
resistance to immunotherapy needs to be validated in the setting of thorough phase II 
or III clinical trials. Confirmation of this preliminary data would be of utmost 
importance for the prospect of patient selection and trial enrichment in current and 
future investigations, and certainly for the precise decision-making in the 
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Molecular classification of HCC based upon immune status. Around 30% of HCCs 
belong to the „Immune class‟, with high levels of immune cell infiltration, expression of 
PD-1 and/or programmed cell death 1 ligand 1 (PD- L1), activation of IFNγ signaling, 
and markers of cytolytic activity (such as granzyme B and perforin 1). This HCC 
tumors are more likely to respond to immune checkpoint inhibitors. On the other 
hand, the „Immune Exclusion class‟ accounting for ~30% of HCCs, is characterized 
by T cell exclusion from the TME and CTNNB1 mutations. Tumors classified within 
the HCC Exclusion class would represent those with innate resistance to anti-PD-
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1/PD-L1 inhibitors. Non-inflamed tumors with wild-type CTNNB1 and intermediate 
levels of immune infiltration (the so called „Immune intermediate class‟) needs to be 
further characterized to be able to anticipate the response that these patients would 
have when treated with immunotherapies. 
 
 
